TSAR Publications：
1. Huang T-W, Yeh T-K, Hsu S-Y, Tan M-C, Huang W-C, Kuo S-C. In vitro and in vivo efficacy of vancomycin against Elizabethkingia species and the impact of increased vancomycin MICs. Microbiol Spectr. 2025 Nov 4;13(11):e0237125. doi: 10.1128/spectrum.02371-25. Epub 2025 Oct 1. PMID: 41031831; PMCID: PMC12584665.
2. Chen PJ, Tan MC, Huang WC, Hsu SY, Chen TL, Yang CY, Kuo SC. The individual contributions of blaB, blaGOB and blaCME on MICs of β-lactams in Elizabethkingia anophelis. J Antimicrob Chemother. 2024 Jul 1;79(7):1577-1580. doi: 10.1093/jac/dkae137. PMID: 38742706; PMCID: PMC11215548.
3. Tan MC, Huang YC, Chen PJ, Huang WC, Hsu SY, Wang HY, Liou CH, Sun JR, Lauderdale TY, Kuo SC. In vitro and in vivo evidence discourages routine testing and reporting of piperacillin/tazobactam susceptibility of Elizabethkingia species. J Antimicrob Chemother. 2024 Jan 3;79(1):200-202. doi: 10.1093/jac/dkad322. PMID: 37850648; PMCID: PMC10761272.
4. Yang YS, Huang TW, Huang YC, Huang WC, Hsu SY, Wu HC, Chen FJ, Shang HS, Sytwu HK, Kuo SC. In vitro and in vivo efficacy of minocycline-based therapy for Elizabethkingia anophelis and the impact of reduced minocycline susceptibility. Int J Antimicrob Agents. 2022 Nov-Dec;60(5-6):106678. doi: 10.1016/j.ijantimicag.2022.106678. Epub 2022 Sep 29. PMID: 36184015.
5. Lee YL, Liu KM, Chang HL, Liao YC, Lin JS, Kung FY, Ho CM, Lin KH, Chen YT. The Evolutionary Trend and Genomic Features of an Emerging Lineage of Elizabethkingia anophelis Strains in Taiwan. Microbiol Spectr. 2022 Feb 23;10(1):e0168221. doi: 10.1128/spectrum.01682-21. Epub 2022 Jan 19. PMID: 35044198; PMCID: PMC8768576.
6. Kuo SC, Tan MC, Huang WC, Wu HC, Chen FJ, Liao YC, Wang HY, Shiau YR, Lauderdale TL. Susceptibility of Elizabethkingia spp. to commonly tested and novel antibiotics and concordance between broth microdilution and automated testing methods. J Antimicrob Chemother. 2021 Feb 11;76(3):653-658. doi: 10.1093/jac/dkaa499. PMID: 33258923; PMCID: PMC8600004.